• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=25623468).
  
• Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (PubMed=27540956).
  
• Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=27540956).
  

DOI=10.1186/1479-5876-12-S1-P7
Azzariti A., Porcelli L., Quatrale A.E., Sidella L., Iacobazzi R.M., Guida G., Maida I., Cocco T., Ferretta A., Strippoli S., Guida S., Tommasi S., Paradiso A., Guida M.
Barasertib: a novel approach for the treatment of metastatic melanoma.
J. Transl. Med. 12 Suppl. 1:P7-P7(2014)

PubMed=25623468; DOI=10.1186/s12967-015-0385-4; PMCID=PMC4314759
Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I., Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S., Tommasi S., Guida M., Azzariti A.
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
J. Transl. Med. 13:26.1-26.13(2015)

PubMed=27540956; DOI=10.1111/pcmr.12516
Guida M., Strippoli S., Ferretta A., Bartolomeo N., Porcelli L., Maida I., Azzariti A., Tommasi S., Grieco C., Guida S., Albano A., Lorusso V., Guida G.
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.
Pigment Cell Melanoma Res. 29:679-687(2016)